Institution: | 1. Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran;2. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Department of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
Student Research Committee, Iran University of Medical Sciences, Tehran, Iran;3. Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran;4. Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Department of Pharmacognosy, Faculty of Pharmacy and Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran;5. Department of Physiology, Medical School, Ardabil University of Medical Sciences, Ardabil, Iran;6. Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran |
Abstract: | Acute myocardial infarction (AMI) is one of the leading causes of morbidity worldwide. Myocardial reperfusion is known as an effective therapeutic choice against AMI. However, reperfusion of blood flow induces ischemia/reperfusion (I/R) injury through different complex processes including ion accumulation, disruption of mitochondrial membrane potential, the formation of reactive oxygen species, and so forth. One of the processes that gets activated in response to I/R injury is autophagy. Indeed, autophagy acts as a “double-edged sword” in the pathology of myocardial I/R injury and there is a controversy about autophagy being beneficial or detrimental. On the basis of the autophagy effect and regulation on myocardial I/R injury, many studies targeted it as a therapeutic strategy. In this review, we discuss the role of autophagy in I/R injury and its targeting as a therapeutic strategy. |